NCT00425191已完成2 期
A Multicenter, Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 165
- 试验地点
- 1
- 主要终点
- Response Rate
研究概览
简要总结
To assess the antitumour activity (response rate) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of two different combinations of docetaxel and gemcitabine and of a sequential treatment of cisplatin /gemcitabine followed by docetaxel as first line chemotherapy · To evaluate the quantitative and qualitative toxicity of each treatment arms.· To determine time to progression, duration of response, time to treatment failure, and overall survival in each group.· To evaluate changes from baseline in the Lung Cancer Symptom Scale of patients in each treatment arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of NSCLC istologic subtypes may include large cell, squamous cell, or adenocarcinoma or a generic cytological diagnosis of NSCLC;
- •Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage IIIB (only N3 supraclavicular or T4 for pleural effusion) or Stage IV according to the revised International Staging System
- •Patients must have at least one measurable lesion;
- •Previous radical surgery (more 30 days before study entry) is allowed but a pathologic proof of progression of neoplastic disease must be documented whenever possible;
- •Weight loss < = 5% within the last 3 months;
- •Laboratory requirements at entry :
- •Blood cell counts: Absolute neutrophils > 2.0 x 109/LPlatelets > 100 x 109/LHemoglobin > 10 g/dl
- •Renal function:Serum creatinine < 1 upper normal limits (UNL). In case of limit value of serum creatinine, the creatinine clearance should be > 60 mL/min
- •Hepatic functions:Serum bilirubin < 1 x UNLASAT and ALAT < 2.5 x UNLAlkaline phosphatase < 5 x UNL (unless accompanied by extensive bone metastases);
- •Exclusion criteria:
- •Prior systemic chemotherapy or immunotherapy including neoadjuvant or adjuvant treatments;
- •Prior radiotherapy for NSCLC;
- •Cyto-histological diagnosis of small cell lung cancer, carcinoid, or mixed small-cell / non-small cell lung cancer;
- •Patients with not measurable disease only;
- •Patients with symptomatic brain metastases or with leptomeningeal disease. However; patients with symptomatic brain metastases who become asymptomatic under corticosteriods treatment can enter the study;
- •History of prior malignancies, except for cured non melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years;
- •History of hypersensitivity reaction to polysorbate 80;
- •Pregnant or lactating women (women of childbearing potential must use adequate contraception);
- •Concurrent treatment with other experimental drugs;
- •Current peripheral neuropathy NCI grade > = 2;
- •Significant neurological or psychiatric disorders;
- •Hepatic functions abnormalities;
- •Participation in clinical trials with other experimental agents within 30 days of study entry;
- •Other serious concomitant illness of medical conditions;
- •History of significant neurologic or psychiatric disorders including demential or seizures;
- •Active infection requiring iv antibiotics;
- •Active ulcer, unstable diabetes mellitus or other contra-indication to corticotherapy;
- •Any other condition, which in the judgement of the investigator would place the subject at, undoes risk or interferes with the study.
- •Treatment with biphosphonates.
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: Docetaxel and Gemcitabine (Drug)
2
Experimental
干预措施: Docetaxel and Gemcitabine (Drug)
3
Experimental
干预措施: Gemcitabine cisplatin followed by docetaxel (Drug)
结局指标
主要结局
Response Rate
时间窗: Performed after 3 cycles and at the end of treatment (6 cycles).
次要结局
- Time to progression.(Time from treatment to the documented profession of disease.)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal CancerColorectal NeoplasmsNCT02842580Federation Francophone de Cancerologie Digestive21
已完成
1 期
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugAdvanced Solid TumorsNCT04095273Bayer56
已完成
不适用
Anti-tumor efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural EffusioNeoplasmsKCT0003232Asan Medical Center63
进行中（未招募）
1 期
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Urothelial CarcinomaNon-mucosal MelanomaRenal Cell CarcinomaMelanomaNCT05661955BeiGene113
已完成
2 期
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLCCarcinoma, Non-Small-Cell LungNCT00252382Sunesis Pharmaceuticals31